Literature DB >> 15210705

Co-expression of nicastrin and presenilin rescues a loss of function mutant of APH-1.

Dieter Edbauer1, Christoph Kaether, Harald Steiner, Christian Haass.   

Abstract

gamma-Secretase is an intramembrane-cleaving aspartyl protease complex that mediates the final cleavage of beta-amyloid precursor protein to liberate the neurotoxic amyloid-beta peptide implicated in Alzheimer's disease. The four proteins presenilin (PS), nicastrin (NCT), APH-1, and PEN-2 are sufficient to reconstitute gamma-secretase activity in yeast. Although PS seems to contribute the catalytic core of the gamma-secretase complex, no distinct function could be attributed to the other components so far. In Caenorhabditis elegans, mutation of a glycine to an aspartic acid within a conserved GXXXG motif in the fourth transmembrane domain of APH-1 causes a loss of function phenotype. Surprisingly, we now found that the human homologue APH-1a carrying the equivalent mutation G122D is fully active in yeast co-expressing PS1, NCT, and PEN-2. To address this discrepancy, we expressed APH-1a G122D in HEK293 cells. As reported previously, overexpressed APH-1a G122D was not incorporated into the gamma-secretase complex. Separate overexpression of PS1, NCT, or PEN-2 together with APH-1a G122D allowed the formation of heterodimers lacking the other endogenous components. Only the combined overexpression of PS1 and NCT together with APH-1a G122D facilitated the formation of a fully active gamma-secretase complex. Under these conditions, APH-1a G122D supported the production of normal amounts of Abeta. We conclude that cooperative effects may stabilize a trim-eric complex of APH-1a G122D together with PS1 and NCT. Upon successful complex assembly, the GXXXG motif becomes dispensable for gamma-secretase activity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15210705     DOI: 10.1074/jbc.M406228200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Characterization of APH-1 mutants with a disrupted transmembrane GxxxG motif.

Authors:  Wataru Araki; Shinya Saito; Noriko Takahashi-Sasaki; Hirohisa Shiraishi; Hiroto Komano; Kiyoko S Murayama
Journal:  J Mol Neurosci       Date:  2006       Impact factor: 3.444

Review 2.  Assembly, maturation, and trafficking of the gamma-secretase complex in Alzheimer's disease.

Authors:  Daniel R Dries; Gang Yu
Journal:  Curr Alzheimer Res       Date:  2008-04       Impact factor: 3.498

3.  BRI2 homodimerizes with the involvement of intermolecular disulfide bonds.

Authors:  Maria Tsachaki; Jorge Ghiso; Agueda Rostagno; Spiros Efthimiopoulos
Journal:  Neurobiol Aging       Date:  2008-04-28       Impact factor: 4.673

4.  Chemical cross-linking provides a model of the gamma-secretase complex subunit architecture and evidence for close proximity of the C-terminal fragment of presenilin with APH-1.

Authors:  Harald Steiner; Edith Winkler; Christian Haass
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

5.  Structure of gamma-secretase and its trimeric pre-activation intermediate by single-particle electron microscopy.

Authors:  Fabiana Renzi; Xulun Zhang; William J Rice; Celia Torres-Arancivia; Yacob Gomez-Llorente; Ruben Diaz; Kwangwook Ahn; Chunjiang Yu; Yue-Ming Li; Sangram S Sisodia; Iban Ubarretxena-Belandia
Journal:  J Biol Chem       Date:  2011-03-17       Impact factor: 5.157

6.  Neuronal or glial expression of human apolipoprotein e4 affects parenchymal and vascular amyloid pathology differentially in different brain regions of double- and triple-transgenic mice.

Authors:  Tom Van Dooren; David Muyllaert; Peter Borghgraef; Annelies Cresens; Herman Devijver; Ingrid Van der Auwera; Stefaan Wera; Ilse Dewachter; Fred Van Leuven
Journal:  Am J Pathol       Date:  2006-01       Impact factor: 4.307

Review 7.  BACE and gamma-secretase characterization and their sorting as therapeutic targets to reduce amyloidogenesis.

Authors:  Neville Marks; Martin J Berg
Journal:  Neurochem Res       Date:  2009-09-17       Impact factor: 3.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.